1. Israel Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
BioLineRx Ltd.

BioLineRx Ltd.

BLRX.TA
BioLineRx Ltd.IL flagTel Aviv Stock Exchange
1.50
ILA
- -
- -
39.16MMarket Cap
BioLineRx Ltd.
BLRX.TA
(Tel Aviv Stock Exchange)

Recent

price

1.50

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
2.58
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.02
- -
- -
Revenue per Share
0.17
-1.07
-1.21
-0.76
-0.34
-0.28
-0.28
-0.27
-0.21
-0.17
-0.12
-0.04
-0.03
-0.06
-0.01
- -
- -
Basic EPS, GAAP
0.87
-0.93
-1.2
-0.87
-0.49
-0.33
-0.26
-0.28
-0.32
-0.16
-0.09
-0.04
-0.03
-0.02
-0.04
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
-7.8
-6.99
-5.93
-4.44
-3.07
-3.09
-2.19
-2.02
-1.66
-1.06
-0.43
-0.39
-0.37
-0.3
-0.13
-0.13
Book Value per Share
- -
1.8
0.87
0.51
0.98
0.92
0.62
0.51
0.18
0.08
- -
0.07
0.04
- -
- -
- -
- -
Tangible Book Value per Share
12
12
17
22
32
51
56
90
109
146
253
663
774
963
1,198
2,465
2,546
Basic Weighted Avg Shares
32
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
5
29
1
1
Sales/Revenue/Turnover
11.61
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-895.65
-66.18
-871.78
-777.46
Operating Margin (%)
1
- -
- -
- -
- -
- -
- -
- -
1
1
1
1
1
1
4
1
- -
Depreciation Expense
2
-13
-20
-17
-11
-14
-16
-24
-23
-25
-30
-27
-25
-61
-9
-1
-8
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
6.57
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-1,262.79
-31.86
-99.58
-563.69
Profit Margin (%)
- -
20
16
16
32
45
32
44
25
16
12
48
41
4
12
12
8
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
8
8
4
2
10
8
10
5
4
LT Debt
- -
23
15
12
32
48
35
53
41
33
22
68
51
13
13
23
21
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
5
5
5
LT Borrowings
6
4
3
LT Finance Leases
1
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
2,611
2,611
2,611
Market Capitalization
1,664
1,204
1,052

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
29
24
22
Cash, Cash Equivalents & STI
25
21
17
Accounts Receivable, Net
- -
- -
- -
Inventories
2
2
2
Total Current Liabilities
14
12
14
Payables & Accruals
6
5
7
ST Debt
5
5
5
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
13.44%
36.99%
73.43%
Free Cash Flow
7.4%
2.13%
-81.56%
Net Income, GAAP
4.01%
-9.35%
-87.26%
Sales/Revenue/Turnover
- -
- -
-95.92%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
7
5
5
12
29
2025
- -
- -
- -
- -
1
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
-0.01
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
XORTX Therapeutics Inc. (XRTX.V)
PepGen Inc. (PEPG)
4D pharma plc (LBPS)
Field Trip Health & Wellness Ltd. (FTHWF)
Caribou Biosciences, Inc. (CRBU)
Intellia Therapeutics, Inc. (0JBU.L)
Business
BioLineRx Ltd. (NASDAQ/TASE: BLRX) develops and commercializes innovative therapeutics for oncology and rare diseases; the company focuses on advancing novel drug candidates through clinical development, leveraging expertise in stem cell mobilization, immuno-oncology, and targeted cancer therapies. Founded in 2003 and headquartered at 2 HaMa’ayan Street, Modi’in Technology Park, Hevel Modi’in, Israel, BioLineRx operates primarily in the United States and Israel, with strategic partnerships extending development and commercialization rights into Asia and other global territories. The company's lead product, APHEXDA (motixafortide), a high-affinity CXCR4 peptide inhibitor, is FDA-approved for stem cell mobilization in combination with filgrastim (G-CSF) for autologous transplantation in multiple myeloma patients; motixafortide is also in Phase 2b trials for first-line metastatic pancreatic ductal adenocarcinoma (PDAC) in combination with cemiplimab and chemotherapy (CheMo-4-METPANC study sponsored by Columbia University), Phase 1 trials for sickle cell disease stem cell mobilization (collaborations with Washington University and St. Jude Children’s Research Hospital), and subject to bridging studies for multiple myeloma in China. BioLineRx's pipeline emphasizes motixafortide's broad applicability across hematopoietic stem cell mobilization, solid tumors, and rare hematologic disorders, targeting unmet needs in cancer stem cell therapy and immune cell recruitment. In November 2024, BioLineRx entered an exclusive licensing agreement with Ayrmid Ltd. (parent of Gamida Cell) granting Ayrmid global rights (excluding Asia and solid tumors) to develop and commercialize APHEXDA, providing $10 million upfront, up to $87 million in milestones, 18-23% royalties, and a $9 million equity investment from Highbridge Capital Management, alongside significant cash burn reduction to extend runway into 2026; in October 2023, BioLineRx partnered with Guangzhou Gloria Biosciences for Asian rights to motixafortide across indications, including $15 million upfront, up to $250 million in milestones, and a $14.6 million equity investment, with GloriaBio advancing PDAC and multiple myeloma bridging studies in China and Japan. These non-dilutive deals support BioLineRx's transition to a lean development model, funding pipeline progression while generating initial APHEXDA revenues of $7.9 million in Q3 2024.